Ascending Aortic Prosthesis and acessories Իսրայել - եբրայերեն - Ministry of Health

ascending aortic prosthesis and acessories

קיור מדיקל אנד טכניקל סופלאי - רופא - משתלים לבביים המכילים חומר מן החי

דספרל 0.5 גרם Իսրայել - եբրայերեն - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

דספרל 0.5 גרם Իսրայել - եբրայերեն - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

דספרל 0.5 גרם Իսրայել - եբրայերեն - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

בוטומידור 10 מג מל וטרינרי Իսրայել - եբրայերեն - Ministry of Health

בוטומידור 10 מג מל וטרינרי

vetmarket ltd, israel - butorphanol as tartrate - תמיסה להזרקה - butorphanol as tartrate 10 mg/ml

גרדסיל 9 Իսրայել - եբրայերեն - Ministry of Health

גרדסיל 9

merck sharp & dohme (israel - 1996) company ltd, israel - hpv type 11 l1 protein; hpv type 16 l1 protein; hpv type 18 l1 protein; hpv type 31 l1 protein; hpv type 33 l1 protein; hpv type 45 l1 protein; hpv type 52 l1 protein; hpv type 58 l1 protein; hpv type 6 l1 protein - תרחיף להזרקה - hpv type 58 l1 protein 20 mcg / 0.5 ml; hpv type 52 l1 protein 20 mcg / 0.5 ml; hpv type 45 l1 protein 20 mcg / 0.5 ml; hpv type 33 l1 protein 20 mcg / 0.5 ml; hpv type 31 l1 protein 20 mcg / 0.5 ml; hpv type 18 l1 protein 40 mcg / 0.5 ml; hpv type 16 l1 protein 60 mcg / 0.5 ml; hpv type 11 l1 protein 40 mcg / 0.5 ml; hpv type 6 l1 protein 30 mcg / 0.5 ml - papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)

סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP Իսրայել - եբրայերեն - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP Իսրայել - եբրայերեն - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP Իսրայել - եբրայերեն - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride

בינוקריט 1000 יחבל 0.5 מל Իսրայել - եբրայերեն - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob